At this time of year Cramer says certain stocks become anointed by Wall Street. That is, select names will attract buyers simply because they've already made big gains.
"Through the end of the year money managers often buy these winners, if only to show clients how smart they are," Cramer explained.
Because Cramer believes these winners will keep on winning due to the mechanics of the money management business, he advocates buying now – ahead of an expected advance.
"And when you look at 2013's best performing health care stocks in the S&P 500 the top pure biotech plays are Celgene, Regeneron, and Gilead," Cramer said.
The phenomenon of window dressing would suggest these stocks should have more room to run. But do they? To either confirm or deny the thesis, Cramer often consults technical analysis. The following technical analysis was provided by Bob Lang, the founder and senior strategist at ExplosiveOptions.net.